

**Supplemental Digital Content 13. Table: Clinical and demographic characteristics of MIS-C patients per SARS-CoV-2 variant phase**

Characteristic	Individual phases					Omicron/Population Immunity versus other phases		
	Wild-type, N = 76	Alpha, N = 26	Delta, N = 67	Omicron, N = 20	Population Immunity, N = 0	WT/Alpha/Delta, N = 169	Omicron/Population immunity, N = 20	p-value
Age (continuous)	10.7 (7.9, 14.0)	10.6 (8.4, 13.3)	7.9 (5.8, 11.1)	10.1 (5.2, 12.3)	No cases	10.0 (6.8, 12.0)	10.1 (5.2, 12.3)	0.94
Medical history present	30% (23/76)	31% (8/26)	36% (24/66)	40% (8/20)	No cases	33% (55/168)	40% (8/20)	0.67
Abnormal neurocognitive development	2.7% (2/75)	0% (0/25)	3.1% (2/65)	15% (3/20)	No cases	2.4% (4/165)	15% (3/20)	0.074
History of pulmonary condition	6.7% (5/75)	7.7% (2/26)	1.5% (1/66)	5.0% (1/20)	No cases	4.8% (8/167)	5.0% (1/20)	1.0
ICU admission	64% (49/76)	58% (15/26)	51% (34/67)	40% (8/20)	No cases	58% (98/169)	40% (8/20)	0.23
length of hospitalization	7.0 (5.0, 9.0)	5.0 (4.0, 6.8)	4.0 (3.0, 6.0)	4.0 (2.0, 6.0)	No cases	5.0 (4.0, 7.0)	4.0 (2.0, 6.0)	0.045
Severe disease	49% (37/76)	46% (12/26)	42% (28/67)	20% (4/20)	No cases	46% (77/169)	20% (4/20)	0.074

Clinical characteristics of patients at different SARS-CoV-2 phases. Descriptive statistics are shown for alle individual phases and inferential statistics are presented to test for differences between the pre-omicron variants (wild-type, alpha, and delta) versus omicron and population immunity phases. Continuous values are described with the median and interquartile ranges and the Wilcoxon rank sum test was used for statistical testing. For categorical values the count, numerator and percentage are shown and the Pearson's Chi-squared test, and the Fisher's exact test where appropriate, were used for statistical testing.